|
|
Vaccine Detail
|
Autologous Tumor Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Autologous Tumor Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007319
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- CD86
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: Vaccination consisted of autologous cells cultured from primary tumor or resected metastasis, transduced to express B7.1 surface molecule and then irradiated (Fishman et al., 2008).
- Description: A therapeutic agent produced by isolating tumor cells from an individual and processing these tumor cells into a vaccine formulation in vitro; the vaccine is then administered to the individual from whom the tumor cells were isolated. Typically combined with an adjuvant immunostimulant, an autologous cell vaccine may elicit a cytotoxic T-lymphocytic immune response to cell surface-expressed tumor-associated antigens (TAAs), resulting in tumor cell death. (NCIT_C1980).
This vaccine has been used in trials involving mantle cell lymphoma and colon cancer. (Hanna, 2012; Frank et al., 2020)
|
| Host Response |
|
|
| References |
Fishman et al., 2008: Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 2008; 31(1); 72-80. [PubMed: 18157014].
Frank et al., 2020: Frank MJ, Khodadoust MS, Czerwinski DK, Haabeth OAW, Chu MP, Miklos DB, Advani RH, Alizadeh AA, Gupta NK, Maeda LS, Reddy SA, Laport GG, Meyer EH, Negrin RS, Rezvani AR, Weng WK, Sheehan K, Faham M, Okada A, Moore AH, Phillips DL, Wapnir IL, Brody JD, Levy R. Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. The Journal of experimental medicine. 2020; 217(9); . [PubMed: 32558897].
Hanna, 2012: Hanna MG Jr. Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer. Human vaccines & immunotherapeutics. 2012; 8(8); 1156-1160. [PubMed: 22854664].
NCIT_C1980: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1980]
|
|
